TAK-951
/ Takeda
- LARVOL DELTA
Home
Next
Prev
1 to 16
Of
16
Go to page
1
January 10, 2025
A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)
(clinicaltrials.gov)
- P1 | N=1 | Terminated | Sponsor: Takeda
New P1 trial • Rare Diseases
September 24, 2024
A Study of TAK-951 in Healthy Adults
(clinicaltrials.gov)
- P1 | N=48 | Terminated | Sponsor: Takeda
New P1 trial
March 10, 2023
A Study of TAK-951 in Healthy Adults
(clinicaltrials.gov)
- P1 | N=32 | Completed | Sponsor: Takeda | N=138 ➔ 32
Enrollment change
July 23, 2022
A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery
(clinicaltrials.gov)
- P2 | N=80 | Completed | Sponsor: Takeda | Active, not recruiting ➔ Completed | Trial completion date: Dec 2022 ➔ Mar 2022 | Trial primary completion date: Dec 2022 ➔ Mar 2022
Trial completion • Trial completion date • Trial primary completion date
March 24, 2022
A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery
(clinicaltrials.gov)
- P2 | N=100 | Recruiting | Sponsor: Takeda | Trial completion date: Jan 2022 ➔ Dec 2022 | Trial primary completion date: Jan 2022 ➔ Dec 2022
Trial completion date • Trial primary completion date
November 19, 2021
A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery
(clinicaltrials.gov)
- P2; N=100; Recruiting; Sponsor: Takeda; N=160 ➔ 100
Clinical • Enrollment change
September 16, 2021
A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery
(clinicaltrials.gov)
- P2; N=160; Recruiting; Sponsor: Takeda; N=100 ➔ 160
Clinical • Enrollment change
August 18, 2021
A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery
(clinicaltrials.gov)
- P2; N=100; Recruiting; Sponsor: Takeda; Trial primary completion date: Jul 2021 ➔ Nov 2021
Clinical • Trial primary completion date
June 03, 2021
A Study of TAK-951 in Healthy Adults
(clinicaltrials.gov)
- P1; N=138; Completed; Sponsor: Takeda; Recruiting ➔ Completed; N=40 ➔ 138
Clinical • Enrollment change • Trial completion
February 21, 2021
A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery
(clinicaltrials.gov)
- P2; N=100; Recruiting; Sponsor: Takeda; Trial completion date: Apr 2021 ➔ Aug 2021; Trial primary completion date: Apr 2021 ➔ Jul 2021
Clinical • Trial completion date • Trial primary completion date
January 25, 2021
TAK-951 Versus Ondansetron in Prophylaxis for Postoperative Nausea and Vomiting in High-Risk Participants
(clinicaltrials.gov)
- P2; N=100; Recruiting; Sponsor: Takeda; Active, not recruiting ➔ Recruiting
Clinical • Enrollment open
December 19, 2020
TAK-951 Versus Ondansetron in Prophylaxis for Postoperative Nausea and Vomiting in High-Risk Participants
(clinicaltrials.gov)
- P2; N=100; Active, not recruiting; Sponsor: Takeda; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed
October 22, 2020
TAK-951 Versus Ondansetron in Prophylaxis for Postoperative Nausea and Vomiting in High-Risk Participants
(clinicaltrials.gov)
- P2; N=100; Recruiting; Sponsor: Takeda; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
October 05, 2020
A Study to Evaluate the Safety,Tolerability, and Pharmacokinetics (PK) of TAK-951 in Healthy Participants Following Intravenous Administration
(clinicaltrials.gov)
- P1; N=40; Recruiting; Sponsor: Takeda; Not yet recruiting ➔ Recruiting; Trial completion date: Jan 2021 ➔ Apr 2021; Trial primary completion date: Jan 2021 ➔ Apr 2021
Clinical • Enrollment open • Trial completion date • Trial primary completion date
September 19, 2020
TAK-951 Versus Ondansetron in Prophylaxis for Postoperative Nausea and Vomiting in High-Risk Participants
(clinicaltrials.gov)
- P2; N=100; Not yet recruiting; Sponsor: Takeda
Clinical • New P2 trial
July 27, 2020
A Study to Evaluate the Safety,Tolerability, and Pharmacokinetics (PK) of TAK-951 in Healthy Participants Following Intravenous Administration
(clinicaltrials.gov)
- P1; N=40; Not yet recruiting; Sponsor: Takeda
Clinical • New P1 trial
1 to 16
Of
16
Go to page
1